Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24467125 | 0.82 | ALOX15 (0.37) | SMN1; SMN2ALOX15CTSK | |
| Hydrochloric Acid SCHEMBL8467904 | 0.78 | ALOX15 (0.37) | SMN1; SMN2ALOX15KDM1A | |
| Hydrochloric Acid SCHEMBL8469215 | 0.78 | ALOX15 (0.37) | SMN1; SMN2ALOX15KDM1A | |
| SCHEMBL18411281 | 0.76 | ALOX15 (0.39) | SMN1; SMN2ALOX15KDM1A | |
| SCHEMBL1485782 | 0.75 | ALOX15 (0.38) | SMN1; SMN2ALOX15CTSK | |
| SCHEMBL1485781 | 0.75 | ALOX15 (0.38) | SMN1; SMN2ALOX15CTSK | |
| SCHEMBL24087422 | 0.75 | ALOX15 (0.38) | SMN1; SMN2ALOX15CTSK | |
| Hydrochloric Acid SCHEMBL8461802 | 0.75 | ALOX15 (0.34) | SMN1; SMN2ALOX15KDM1A | |
| SCHEMBL25477987 | 0.74 | HDAC4 (0.32) | SMN1; SMN2ALOX15CTSK | |
| SCHEMBL368190 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180212160-A1 | LUMINESCENT PALLADIUM(0) AND PLATINUM(0) CARBENE COMPLEXES FOR OLEDS | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2018-07-26 | — | — | US | disclosed |
| EP-2970207-B1 | SUBSTITUTED PIPERIDINE COMPOUNDS AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-16 | — | — | EP | disclosed |
| US-9695183-B2 | Substituted 7-azabicycles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-04 | — | — | US | disclosed |
| US-9611262-B2 | Substituted 2-azabicycles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-04 | — | — | US | disclosed |
| US-9611277-B2 | Substituted 2-azabicycles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180212160-A1 | LUMINESCENT PALLADIUM(0) AND PLATINUM(0) CARBENE COMPLEXES FOR OLEDS | ZC3HAV1L, OCIAD1, ZKSCAN2 | SMN1; SMN2 3116/4885ALOX15 532/4885TAAR1 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.